Table 3.
Sensitivity analysis of the association between LXA4 and the incidence of T2DM.
| N (case) | Model 1 | P value | Model 2 | P value | Model 3 | P value | |
|---|---|---|---|---|---|---|---|
| HR (95% CI) | HR (95% CI) | HR (95% CI) | |||||
| Excluding participants with hs-CRP > 5 mg/L | |||||||
| Q 1 | 671 (52) | Ref | 1.0 | Ref | 1.0 | Ref | 1.0 |
| Q 2 | 655 (39) | 0.75 (0.50-1.14) | 0.181 | 0.80 (0.52-1.21) | 0.279 | 0.85 (0.56-1.29) | 0.447 |
| Q 3 | 666 (43) | 0.82 (0.55-1.23) | 0.346 | 0.86 (0.57-1.29) | 0.453 | 0.82 (0.55-1.24) | 0.346 |
| Q 4 | 678 (31) | 0.58 (0.37-0.90) | 0.016 | 0.61 (0.39-0.95) | 0.030 | 0.58 (0.37-0.91) | 0.018 |
| P trend | 0.029 | 0.029 | 0.049 | 0.022 | |||
| LXA4 > 2.84 ng/mL | 909 (41) | 0.63 (0.45-0.90) | 0.011 | 0.65 (0.46-0.93) | 0.018 | 0.60 (0.42-0.85) | 0.005 |
| Per 1-SD increase | 0.77 (0.51-1.18) | 0.229 | 0.79 (0.53-1.18) | 0.252 | 0.77 (0.50-1.18) | 0.230 | |
| Excluding participants using lipid-lowering drugs | |||||||
| Q 1 | 689 (51) | Ref | 1.0 | Ref | 1.0 | Ref | 1.0 |
| Q 2 | 679 (40) | 0.78 (0.52-1.18) | 0.243 | 0.82 (0.54-1.25) | 0.356 | 0.88 (0.58-1.34) | 0.550 |
| Q 3 | 678 (47) | 0.93 (0.62-1.38) | 0.711 | 0.96 (0.65-1.44) | 0.858 | 0.95 (0.63-1.41) | 0.785 |
| Q 4 | 690 (29) | 0.56 (0.35-0.88) | 0.012 | 0.58 (0.37-0.92) | 0.020 | 0.56 (0.35-0.89) | 0.013 |
| P trend | 0.035 | 0.035 | 0.053 | 0.029 | |||
| LXA4 > 2.84 ng/mL | 934 (41) | 0.62 (0.44-0.88) | 0.008 | 0.64 (0.45-0.91) | 0.013 | 0.60 (0.42-0.85) | 0.004 |
| Per 1-SD increase | 0.75 (0.48-1.16) | 0.197 | 0.77 (0.51-1.17) | 0.221 | 0.76 (0.49-1.18) | 0.220 | |
| Excluding participants diagnosed with T2DM in 2016 | |||||||
| Q 1 | 684 (41) | Ref | 1.0 | Ref | 1.0 | Ref | 1.0 |
| Q 2 | 683 (33) | 0.79 (0.50-1.25) | 0.313 | 0.83 (0.53-1.32) | 0.429 | 0.91 (0.57-1.44) | 0.673 |
| Q 3 | 671 (41) | 1.01 (0.66-1.56) | 0.958 | 1.04 (0.67-1.61) | 0.859 | 1.04 (0.67-1.62) | 0.850 |
| Q 4 | 682 (22) | 0.53 (0.31-0.88) | 0.015 | 0.55 (0.33-0.92) | 0.024 | 0.53 (0.31-0.89) | 0.016 |
| P trend | 0.060 | 0.058 | 0.079 | 0.047 | |||
| LXA4 > 2.84 ng/mL | 929 (31) | 0.56 (0.37-0.83) | 0.004 | 0.57 (0.38-0.86) | 0.007 | 0.53 (0.35-0.79) | 0.002 |
| Per 1-SD increase | 0.37 (0.16-0.86) | 0.020 | 0.40 (0.18-0.91) | 0.028 | 0.37 (0.16-0.86) | 0.021 | |
| Changing the adjustment variable BMI to WHR | |||||||
| Q 1 | 689 (52) | Ref | 1.0 | Ref | 1.0 | Ref | 1.0 |
| Q 2 | 676 (41) | 0.79 (0.52-1.19) | 0.256 | 0.80 (0.53-1.22) | 0.299 | 0.89 (0.58-1.35) | 0.571 |
| Q 3 | 685 (46) | 0.88 (0.59-1.31) | 0.529 | 0.90 (0.60-1.35) | 0.607 | 0.91 (0.60-1.36) | 0.631 |
| Q 4 | 705 (33) | 0.61 (0.39-0.94) | 0.026 | 0.66 (0.43-1.02) | 0.062 | 0.64 (0.41-0.99) | 0.046 |
| P trend | 0.052 | 0.051 | 0.108 | 0.067 | |||
| LXA4 > 2.84 ng/mL | 942 (44) | 0.66 (0.47-0.92) | 0.016 | 0.68 (0.48-0.97) | 0.031 | 0.64 (0.45-0.90) | 0.011 |
| Per 1-SD increase | 0.77 (0.51-1.16) | 0.215 | 0.80 (0.55-1.18) | 0.268 | 0.79 (0.53-1.19) | 0.265 | |
Model 1: unadjusted.
Model 2: adjusted for baseline age, gender, BMI (WHR), smoking, alcohol consumption.
Model 3: adjusted for baseline age, gender, BMI (WHR), smoking, alcohol consumption, hypertension, dyslipidemia, hs-CRP, family history of diabetes and physical activity.